All Voice of China 3D Printing

标题: Materialise Reports EUR 67.67 Million Q3 Revenue, EUR 153 Million Cash, and Continued Share Buybacks [打印本页]

作者: admin 时间: 2026-11-4 20:11
标题: Materialise Reports EUR 67.67 Million Q3 Revenue, EUR 153 Million Cash, and Continued Share Buybacks
Nanjixiong introduction: Established European leader Materialise reported nearly 10% medical revenue growth, improving gross margin, more than EUR 150 million in cash, and planned share repurchases. Originating in medical imaging planning software and operating one of Europe's largest printing factories, it is concentrating further on medical growth.

(, 下载次数: 0)

On November 3, 2026, Nanjixiong learned that Materialise NV filed Form 6-K with the U.S. SEC on October 29, Belgian time, disclosing Q3 2026 results signed by CEO Brigitte de Vet-Veithen.

(, 下载次数: 0)

Q3 Revenue EUR 67.67 Million; Gross Margin Reaches 57.7%

Revenue was EUR 67.670 million, versus EUR 66.259 million a year earlier, up 2.1%. Gross profit rose 3.7% to EUR 39.035 million, with margin improving from 56.8% to 57.7%.

Rising margin reflects a better mix, including more high-value medical software and medical printing services.

(, 下载次数: 0)

Combined R&D, sales, and administrative expenses were EUR 38.830 million. R&D was EUR 12.805 million, up 11.9%, supporting next-generation medical software and clinical solutions.

Q3 operating profit was EUR 1.343 million and net profit EUR 1.383 million. First-three-quarter net profit was EUR 6.535 million, versus EUR 1.510 million a year earlier, mainly benefiting from lower financing costs. Financial expenses fell from EUR 7.393 million to EUR 2.699 million.

Three Segments: Medical Exceeds Half of Revenue

Medical revenue was EUR 36.542 million, up 9.7%, approximately 54% of the total. Adjusted EBITDA was EUR 10.015 million, a healthy 27.4% margin. First-three-quarter medical revenue was EUR 106.6 million, with adjusted EBITDA EUR 30.802 million and margin 28.9%.

(, 下载次数: 0)

Software revenue was EUR 9.864 million, adjusted EBITDA EUR 1.463 million, and margin 14.8%. The segment continues providing benchmark tools such as Magics and 3-matic to global medical and industrial users.

(, 下载次数: 0)

Manufacturing revenue was EUR 21.266 million. Its adjusted EBITDA loss narrowed significantly from EUR 845,000 to EUR 257,000. The first-three-quarter cumulative loss narrowed to EUR 262,000.

(, 下载次数: 0)

Medical remains the growth engine, with cumulative revenue up 9.6% and an increasing share. Manufacturing continues narrowing losses by optimizing orders and focusing on high-value customers.

Strong Cash Flow and Continued Repurchases

At September 30, cash and equivalents were EUR 153.53 million, up from EUR 133.92 million at the start of the year. Total debt was EUR 71.056 million, with net cash EUR 82.473 million. Q3 operating cash flow was EUR 9.666 million and free cash flow EUR 11.419 million. Under the announced program, the company cumulatively repurchased 1,426,784 shares for EUR 7.482 million, stated as approximately USD 8.698 million using the ECB September 30 reference rate of EUR 1 = USD 1.1355.

(, 下载次数: 0)

Nanjixiong's Observations

The report shows continued medical investment and nearly double-digit growth, narrowing manufacturing losses through order optimization, and active divestment of noncore businesses such as eyewear to focus on medical software and services. EUR 153 million cash, approximately EUR 82.47 million net cash, and ongoing repurchases demonstrate confidence in long-term development.

Source: Materialise NV SEC Form 6-K, October 29, 2026.
Original: https://investors.materialise.com/node/12796/html

AI-translated from an article by Kuaixiong on Nanjixiong, originally published on 2026-11-03. Text and images retain the original source attribution.
Read the original Chinese article

欢迎光临 All Voice of China 3D Printing (https://www.panda3dp.com/)